A new drug that slows the progression of ALS is exorbitantly expensive, one again raising anger at the pharmaceutical industry for locking life-changing drugs behind high costs.
is reawakening frustration with Big Pharma after its drugmaker priced it at $158,000 annually, leading to exorbitant insurance processes to access it.
Relyvrio, a drug produced by Amylyx Pharmaceutical, has been found to slow the progress of Amyotrophic Lateral Sclerosis, a disease that typically proves fatal within five years. ALS patients suffer a gradual loss of control over their movement, losing the ability to walk and even talk as the disease progresses.
As a result, getting on a drug that slows progression quickly is vital to many patients, but the high price tag set by Amylyx causes insurance companies to lock the drug behind a lengthy application process, and the drug is sometimes cost-prohibitive for patients even with coverage, according to the Associated Press.
"When someone’s lifespan is measured in months, making people go through these multiple rounds of review is just cruel," said Neil Thakur, the chief mission officer at the ALS Association.two ingredients that are relatively inexpensive. Nevertheless, pharmaceutical companies argue the sky-high price of drugs comes as a result of the lengthy approval process imposed by the FDA. Amylyx expects to make a profit of $450 million from Relyvrio, according to the AP.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ALS patients contend with $158K price tag on new drugFor two years, Becky Mourey pushed the Food and Drug Administration to approve an experimental drug for her Lou Gehrig's disease.
Read more »
ALS patients contend with $158K price tag on experimental drugPatients with insurance coverage say the price tag set by drugmaker Amylyx Pharmaceutical is fueling insurance delays or denials, and sometimes exorbitant out-of-pocket expenses.
Read more »
‘Everybody is him’: How Carlos Watkins was latest Cowboys defender to come up bigFRISCO — The Cowboys’ defense has a saying. Defensive end Dorance Armstrong introduced it when addressing reporters following an Oct. 9 win over the Los...
Read more »
Third Point could see big returns from small changes at Bath & Body WorksDan Loeb's hedge fund expects the retailer can resolve many of its issues by bringing more experience to Bath & Body work's board.
Read more »
Super Saturday could bring big deals for holiday shoppersInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Rivals.com - Three-Point Stance: Big visits, programs that will close strong, Ohio State
Read more »